ITHUF Quote, Financials, Valuation and Earnings

Edesa Biotech, Inc. has a net margin of -35.45% compared to iAnthus Capital Holdings, Inc.'s net margin of --. iAnthus Capital Holdings, Inc.'s return on equity of -- beat Edesa Biotech, Inc.'s return on equity of -77.48%.

iAnthus Capital Holdings, Inc. has a consensus price target of --, signalling upside risk potential of 163536.36%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 643.24%. Given that iAnthus Capital Holdings, Inc. has higher upside potential than Edesa Biotech, Inc., analysts believe iAnthus Capital Holdings, Inc. is more attractive than Edesa Biotech, Inc..

iAnthus Capital Holdings, Inc. has a beta of -0.140, which suggesting that the stock is 114.009% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.

iAnthus Capital Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iAnthus Capital Holdings, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.

iAnthus Capital Holdings, Inc. quarterly revenues are $35.4M, which are larger than Edesa Biotech, Inc. quarterly revenues of --. iAnthus Capital Holdings, Inc.'s net income of -$12.5M is lower than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, iAnthus Capital Holdings, Inc.'s price-to-earnings ratio is 18.33x while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iAnthus Capital Holdings, Inc. is 0.24x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience Corp. has a net margin of -35.45% compared to iAnthus Capital Holdings, Inc.'s net margin of -2178.51%. iAnthus Capital Holdings, Inc.'s return on equity of -- beat Lexaria Bioscience Corp.'s return on equity of -147.19%.

iAnthus Capital Holdings, Inc. has a consensus price target of --, signalling upside risk potential of 163536.36%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $4.50 which suggests that it could grow by 703.57%. Given that iAnthus Capital Holdings, Inc. has higher upside potential than Lexaria Bioscience Corp., analysts believe iAnthus Capital Holdings, Inc. is more attractive than Lexaria Bioscience Corp..

iAnthus Capital Holdings, Inc. has a beta of -0.140, which suggesting that the stock is 114.009% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.

iAnthus Capital Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iAnthus Capital Holdings, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.

iAnthus Capital Holdings, Inc. quarterly revenues are $35.4M, which are larger than Lexaria Bioscience Corp. quarterly revenues of $174K. iAnthus Capital Holdings, Inc.'s net income of -$12.5M is lower than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, iAnthus Capital Holdings, Inc.'s price-to-earnings ratio is 18.33x while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iAnthus Capital Holdings, Inc. is 0.24x versus 14.29x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -35.45% compared to iAnthus Capital Holdings, Inc.'s net margin of --. iAnthus Capital Holdings, Inc.'s return on equity of -- beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

iAnthus Capital Holdings, Inc. has a consensus price target of --, signalling upside risk potential of 163536.36%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 513.1%. Given that iAnthus Capital Holdings, Inc. has higher upside potential than Oncolytics Biotech, Inc., analysts believe iAnthus Capital Holdings, Inc. is more attractive than Oncolytics Biotech, Inc..

iAnthus Capital Holdings, Inc. has a beta of -0.140, which suggesting that the stock is 114.009% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

iAnthus Capital Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iAnthus Capital Holdings, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

iAnthus Capital Holdings, Inc. quarterly revenues are $35.4M, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. iAnthus Capital Holdings, Inc.'s net income of -$12.5M is lower than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, iAnthus Capital Holdings, Inc.'s price-to-earnings ratio is 18.33x while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iAnthus Capital Holdings, Inc. is 0.24x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals, Inc. has a net margin of -35.45% compared to iAnthus Capital Holdings, Inc.'s net margin of -867.29%. iAnthus Capital Holdings, Inc.'s return on equity of -- beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.

iAnthus Capital Holdings, Inc. has a consensus price target of --, signalling upside risk potential of 163536.36%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.40 which suggests that it could grow by 24.98%. Given that iAnthus Capital Holdings, Inc. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe iAnthus Capital Holdings, Inc. is more attractive than Xenon Pharmaceuticals, Inc..

iAnthus Capital Holdings, Inc. has a beta of -0.140, which suggesting that the stock is 114.009% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.689%.

iAnthus Capital Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iAnthus Capital Holdings, Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

iAnthus Capital Holdings, Inc. quarterly revenues are $35.4M, which are larger than Xenon Pharmaceuticals, Inc. quarterly revenues of --. iAnthus Capital Holdings, Inc.'s net income of -$12.5M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, iAnthus Capital Holdings, Inc.'s price-to-earnings ratio is 18.33x while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iAnthus Capital Holdings, Inc. is 0.24x versus 465.87x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.